Revolution Medicines Inc (FRA:42Z)
€ 51 0.5 (0.99%) Market Cap: 8.72 Bil Enterprise Value: 7.34 Bil PE Ratio: 0 PB Ratio: 5.72 GF Score: 43/100

Revolution Medicines Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 07:15PM GMT
Release Date Price: €26.6 (+3.91%)
Eric William Joseph JPMorgan Chase;Co.;VP;Senior Analyst

&-&

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Revolution Medicines. And presenting on behalf of the company is CEO, Mark Goldsmith. There will be a Q&A session after the presentation, just raise your hand, wait for the microphone before asking your question and for folks joining via webcast, you can submit questions also via the portal. So with that.

Thanks, Mark.

Mark Goldsmith
Revolution Medicines Inc - President, CEO, Chairman

Good morning, and thank you, Eric and JPMorgan. For the opportunity to provide an update on Revolution Medicines, please review our notice regarding legal disclaimers. Our ambitious goal is to revolutionize treatment for patients with RAS-addicted cancers through the discovery development and delivery of innovative targeted medicines.

Our pipeline of pioneering RAS(ON) inhibitors targets the active oncogenic or on state of RAS cancer drivers of common

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot